Pier Capital LLC Purchases 220,586 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Pier Capital LLC grew its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 20.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,275,885 shares of the company's stock after purchasing an additional 220,586 shares during the quarter. Pier Capital LLC owned about 0.86% of Adaptive Biotechnologies worth $6,533,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Adaptive Biotechnologies during the third quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Adaptive Biotechnologies during the third quarter valued at $34,000. MQS Management LLC acquired a new position in shares of Adaptive Biotechnologies during the second quarter valued at $36,000. Rothschild Investment LLC acquired a new position in shares of Adaptive Biotechnologies during the second quarter valued at $36,000. Finally, Townsquare Capital LLC bought a new stake in Adaptive Biotechnologies in the third quarter valued at about $56,000. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock traded up $0.20 during trading hours on Friday, hitting $6.27. The company's stock had a trading volume of 621,260 shares, compared to its average volume of 1,497,708. The company has a market capitalization of $925.32 million, a PE ratio of -4.68 and a beta of 1.49. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $6.70. The stock has a 50 day moving average of $5.25 and a 200 day moving average of $4.48.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ADPT. Piper Sandler upped their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an "overweight" rating in a report on Monday, November 11th. BTIG Research upped their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, October 2nd.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.